Purchase this article with an account.
Shengyan Liu, Chu Ning Chang, Mohit S Verma, Denise Hileeto, Alex Muntz, Ulrike Stahl, Jill Woods, Lyndon William Jones, Frank Gu; Phenylboronic acid modified mucoadhesive nanoparticles facilitate weekly treatment of dry eye syndrome. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2160.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To develop mucoadhesive nanoparticle drug carriers that improve the precorneal retention of the drugs, and to evaluate their in vivo ocular irritancy response and efficacy in treating experimental dry eye by delivering Cyclosporine A (CycA).
The nanoparticles were formed using block copolymer poly(D,L-lactide)-b-dextran and surface functionalized with phenylboronic acid. The encapsulation and release properties of the nanoparticles were assessed using CycA. Experimental dry eye was induced in mice and treated with CycA loaded nanoparticles (weekly administration) and compared to RESTASIS®, administered three times daily. Assessments included tear volume, fluorescein staining, and histopathology. The nanoparticles, with or without CycA, were administered weekly to one eye of each rabbit, while the contralateral eye served as control. We examined the acute (1 week) and chronic (12 weeks) irritation responses using slit-lamp bio-microscope and histopathology.
The nanoparticles encapsulated up to 11.2 wt% of CycA and sustained the release for 5 days. Histopathology demonstrated that administering CycA-loaded nanoparticles to dry eye-induced mice weekly eliminated inflammatory infiltrates and completely recovered the ocular surface. While thrice daily administration of RESTASIS® also cleared the inflammatory infiltrates, it showed much slower ocular surface recovery. Moreover, the weekly dosage of nanoparticles did not cause any irritation or inflammation throughout acute (1 week) and chronic (12 weeks) irritancy studies.
The mucoadhesive nanoparticle formulation significantly reduced administration frequency without compromising the therapeutic efficacy, while also improving the ocular surface recovery by eliminating irritation associated with frequent administration. The study provides promising results for the potential application of this formulation to dramatically improve therapeutic efficacy in treating anterior eye diseases.
This PDF is available to Subscribers Only